Series - Policy

From secure data sharing to executive expertise and workflow automation, this session highlights the digital and strategic tools that help life science companies scale efficiently. Presentations from ShareVault, PSC Software, and BiotechExec will showcase real-world use cases and member-driven results.

Agenda Overview:

• BIO Business Solutions Overview – unlocking value and savings
• ShareVault – Learn how secure document sharing can accelerate due diligence, streamline fundraising, and safeguard your most critical files.
• PSC Software – Discover how intuitive, scalable platforms like ACE Starter support end-to-end audit workflows, reduce risk, and boost productivity.
• BiotechExec – See how executive-level, fractional leadership can fill critical talent gaps and provide strategic direction for growing companies.
• Live Q&A
• Closing Remarks

BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

Explore financial and HR services that empower life science companies to grow with confidence. Hear from Brex, Aon Risk, and ADP R&D Tax Credit on how to simplify expense management, access turnkey HR support, and capitalize on valuable tax credits.

Agenda Overview:

• BIO Business Solutions Overview - unlocking value and savings.
• Brex – Discover how to streamline company spending and optimize your financial runway with powerful, founder-friendly tools.
• ADP Tax Credits – See how your company’s activities may qualify for valuable federal R&D tax credits and how ADP can help you claim them.
• Aon Risk Insurance – Learn how to manage risk across the life sciences enterprise, from directors & officers (D&O) insurance to data privacy, cyber liability, and clinical trial protection.
• Live Q&A
• Closing Remarks

BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

Explore lab optimization strategies, streamlined contract consolidation, and how to connect with the right experts for regulatory submissions and audit readiness. Hear from American Laboratory Trading (ALT), SU Group, and PSC Biotech as they present cost-effective approaches to enhancing lab operations and ensuring compliance at every growth stage.

Agenda Overview:

• BIO VP of Business Development kicks off the session with practical ways members can unlock value and savings through BIO Business Solutions.
• American Laboratory Trading (ALT) – Discover the benefits of sourcing refurbished lab equipment to lower capital costs while maintaining quality and performance.
• SU Group LLC – Learn how to consolidate equipment service contracts for greater efficiency, cost control, and vendor management.
• PSC Biotech – Get insights into tailored consulting support for regulatory planning, audit readiness, and quality systems implementation.
• Live Q&A
• Closing Remarks

BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

Join Thermo Fisher Scientific for an exclusive webinar introducing a transformative approach to biologics development and clinical scale-up. Their "Path to IND for Biologics" method accelerates the journey from DNA to IND/IMPD submission and first-in-human clinical trials in as few as 9 months. Dr. Elena Gontarz, a leading expert in the biologics industry, will guide you through this innovative process, leveraging AI/ML, transposase technology, and integrated solutions during the session: "Path to IND for Biologics: From DNA to First-in-Human in 9 Months." Following the presentation, Dr. Gontarz will answer audience questions and discuss how these novel strategies can streamline the development of complex biologics, such as Fc-fusion proteins and bispecific antibodies, driving them swiftly from development to commercialization.

Get a sneak peek on this novel platform 

Terms and Conditions: Titer levels provided are estimates based on third party results and may vary depending on molecule type or other factors. Timeline from DNA to drug product and start of clinical trials for all path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized after third party cell line development dates are available and confirmed. 9-month timeline will incur additional risk.

Learn more about Dr. Elena Gontarz's expertise and background:

https://www.patheon.com/us/en/insights-resources/blog/navigating-the-complexities-of-process-performance-qualification.html

https://www.patheon.com/us/en/insights-resources/blog/choosing-a-cdmo-who-is-a-true-bioproduction-expert.html

View this webinar for an in-depth exploration of today's complex global market landscape. This panel will address the challenges of launching new therapies in multiple countries, focusing on early decision points for risk mitigation and maximizing supply chain resiliency. Discover how Cencora's global capabilities and flexible solutions can strengthen supply chain resilience amidst evolving challenges.
 

Moderator: Sandra Anderson, Senior Vice President Commercialization, Cencora

Panelists:

• Glenn Pauly, Chief Commercial Officer, Alzheon
• Graham Goodrich, Chief Commercial Officer, Apnimed
• Leigh Shultz, PhD, Associate Vice President & International Head of Trade Channel Strategy & Enablement, Merck & Co.
• Kevin McDermott, Vice President International Commercialization, Cencora
• Tom Doyle, Head of U.S. Commercial Solutions, Cencora

Through 2027, the FDA is conducting a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program to facilitate CMC development of selected products under investigational new drug applications with potential expedited clinical development timeframes. The pilot is a joint effort by both FDA's Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). Selected drug development programs receive extra opportunities to discuss product-specific CMC concerns with the FDA reviewers through CMC-focused Type B meetings to help product development keep pace with their clinical development.

In combination with PhRMA and the FDA, BIO hosted a webinar to inform BIO and PhRMA's memberships about the CDRP: What sorts of products are eligible, what is needed to apply, and why an IND sponsor of a promising product with an expedited clinical development timeframe would want to enlist in this pilot. This webinar will provide additional insights into the CDRP application process, and the planned public workshop designed to promote innovation and understanding in product development.

More than $4B of deals between biopharma companies and AI specialists were announced last year. Similar to the massive quality leap from GPT-2 to GPT-4 and the record-breaking consumer adoption rates of AI tools, that same exponential progress and uptake is coming to biotech AI. 2024 may bring the first one-trillion-parameter protein language model. Companies are already using AI to program, as opposed to discover, antibodies. This level of opportunity and change brings with it urgency—— companies need to rethink from the ground up how their R&D should work to compete in a new era defined by the intersection of biology, data, and AI.

In this webinar, learn how companies are updating their approach to R&D, with a focus on:

1. AI-Ready Data: Improving generation of high-quality biomedical data to support AI model building and model tuning
2. AI-Enabled Scientists: Integrating the right models directly into scientists’ workflows for everyday use
3. Scalability: Making performance, speed, privacy, and cost tradeoffs for deployment of AI, and connecting the wet and dry labs

The FDA has established the Split Real-Time Application Review (STAR) pilot program. The purpose of this program is to shorten the time from the date of a complete submission to the action date, in allowing earlier patient access to therapies that address an unmet medical need.

In this webinar, FDA staff will give an overview of the program, including the eligibility criteria for the pilot, and will answer your questions about participating in the program.

View this conversation highlighting how BIO member companies are strengthening food security and addressing climate change through biotechnology innovations in crop protection and efficient food production. Learn how regulation and policy can support agricultural innovation to protect our environment and our food supply.